The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS SUMMARY: HSBC Cuts Shell Buts Raises Next

Fri, 01st May 2020 09:32

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday afternoon:

----------

FTSE 100

----------

HSBC CUTS SHELL TO 'HOLD' (BUY)

----------

GOLDMAN SACHS CUTS SHELL B PRICE TARGET TO 1850 (2000) PENCE - 'BUY'

----------

BERENBERG CUTS SHELL B TO 'HOLD' (BUY) - PRICE TARGET 1440 (1450) PENCE

----------

HSBC RAISES NEXT TO 'BUY' ('HOLD') - TARGET 5570 (7050) PENCE

----------

UBS RAISES WHITBREAD TO 'BUY' ('NEUTRAL') - TARGET 3610 (4875) PENCE

----------

LIBERUM CUTS HARGREAVES LANSDOWN TO 'HOLD' ('BUY') - TARGET 1540 (2075) PENCE

----------

BARCLAYS RAISES ST JAMES'S PLACE TARGET TO 1118 (1098) PENCE - 'OVERWEIGHT'

----------

BARCLAYS RAISES ASTRAZENECA PRICE TARGET TO 9200 (9000) PENCE - 'OVERWEIGHT'

----------

JEFFERIES RAISES RECKITT BENCKISER PRICE TARGET TO 5900 (5860) PENCE - 'HOLD'

----------

BARCLAYS RAISES RECKITT BENCKISER PRICE TARGET TO 7900 (6900) PENCE - 'OVERWEIGHT'

----------

BERENBERG RAISES RECKITT BENCKISER PRICE TARGET TO 7450 (7350) PENCE - 'BUY'

----------

HSBC RAISES RECKITT BENCKISER PRICE TARGET TO 7300 (7000) PENCE - 'BUY'

----------

DEUTSCHE BANK RAISES FERGUSON PRICE TARGET TO 6600 (5900) PENCE - 'BUY'

----------

DEUTSCHE BANK CUTS BAE SYSTEMS PRICE TARGET TO 695 (730) PENCE - 'BUY'

----------

CREDIT SUISSE CUTS SHELL PRICE TARGET TO 1700 (1900) PENCE - 'OUTPERFORM'

----------

UBS CUTS INTERCONTINENTAL HOTELS PRICE TARGET TO 3900 (4150) PENCE - 'NEUTRAL'

----------

BERENBERG RAISES BARCLAYS PRICE TARGET TO 160 (150) PENCE - 'BUY'

----------

JPMORGAN RAISES ASTRAZENECA PRICE TARGET TO 9500 (8500) PENCE - 'OVERWEIGHT'

----------

JPMORGAN CUTS MELROSE INDUSTRIES PRICE TARGET TO 165 (180) PENCE - 'OVERWEIGHT'

----------

JEFFERIES RAISES SHELL PRICE TARGET TO 1150 (1140) PENCE - 'HOLD'

----------

RBC RAISES SHELL B PRICE TARGET TO 1800 (1700) PENCE - 'OUTPERFORM'

----------

GOLDMAN SACHS RAISES RECKITT BENCKISER PRICE TARGET TO 6300 (5950) PENCE - 'NEUTRAL'

----------

GOLDMAN SACHS CUTS INTERNATIONAL CONSOLIDATED AIRLINES TO 'NEUTRAL' (BUY) - PRICE TARGET 250 (500) PENCE

----------

CREDIT SUISSE RAISES RECKITT BENCKISER PRICE TARGET TO 6100 (5900) PENCE - 'NEUTRAL'

----------

DZ BANK RAISES FAIR VALUE FOR RECKITT BENCKISER TO 7100 (6500) PENCE - 'BUY'

----------

DZ BANK RAISES FAIR VALUE FOR GLAXOSMITHKLINE TO 1950 (1900) PENCE - 'BUY'

----------

RBC RAISES RECKITT BENCKISER PRICE TARGET TO 4900 (4600) PENCE - 'UNDERPERFORM'

----------

DZ BANK RAISES FAIR VALUE FOR ASTRAZENECA TO 7300 (6500) PENCE - 'SELL'

----------

RBC CUTS RSA INSURANCE PRICE TARGET TO 550 (600) PENCE - 'OUTPERFORM'

----------

CREDIT SUISSE RAISES ASHTEAD GROUP TARGET TO 2500 (2050) PENCE - 'OUTPERFORM'

----------

FTSE 250

----------

BARCLAYS CUTS JOHN LAING PRICE TARGET TO 425 (440) PENCE - 'EQUAL WEIGHT'

----------

LIBERUM CUTS RATHBONE BROTHERS PRICE TARGET TO 1520 (2100) PENCE - 'HOLD'

----------

LIBERUM RAISES INTEGRAFIN PRICE TARGET TO 455 (435) PENCE - 'HOLD'

----------

LIBERUM CUTS QUILTER PRICE TARGET TO 145 (185) PENCE - 'BUY'

----------

LIBERUM CUTS BREWIN DOLPHIN HOLDINGS PRICE TARGET TO 330 (384) PENCE - 'BUY'

----------

CREDIT SUISSE CUTS IMI PRICE TARGET TO 800 (950) PENCE - 'UNDERPERFORM'

----------

JPMORGAN RAISES CONVATEC PRICE TARGET TO 167 (160) PENCE - 'UNDERWEIGHT'

----------

JPMORGAN CUTS KAZ MINERALS PRICE TARGET TO 380 (400) PENCE - 'NEUTRAL'

----------

BERENBERG RAISES SYNTHOMER PRICE TARGET TO 330 (260) PENCE - 'BUY'

----------

CREDIT SUISSE RAISES CONVATEC PRICE TARGET TO 180 (175) PENCE - 'UNDERPERFORM'

----------

OTHER MAIN MARKET AND AIM

----------

BERENBERG INITIATES AB DYNAMICS WITH 'BUY' - TARGET 2050 PENCE

----------

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.